FDA RECALLS & COURT ACTIONS: May 5, 1993
Executive Summary
CLASS II - CYTOTEC (MISOPROSTOL) TABLETS, 200 MCG In unit dose bottles of 60 and 100, in cartons of 100 unit dose tablets, and in physician sample packs of 12, an Rx oral tablet indicated for the prevention of NSAID-induced gastric ulcers. Recall number: D-246-3. Lot numbers: 3A382, 3B383, 3B383A, 3B384, 3B386. Manufacturer: G. D. Searle & Company, Gaguas, Puerto Rico. Recalled by: G. D. Searle & Company, Skokie, Illinois, by letter April 22, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 39,276 physician samples, 368 unit dose cartons, 21,621 bottles of 100 and 6,128 bottles of 60 were distributed; firm estimates 60% of the product remains on the market. Reason: Presence of Pseudomonas bacteria. CLASS II - PERITRATE SA (PENTAERYTHRITOL TETRANITRATE) Sustained Action Tablets, in bottles of 100, indicated for the relief of angina pectoris. Recall number: D-245-3. Lot numbers: 16101VA, 07751VA, 07751VB. Manufacturer: Warner Lambert, Inc., Vega Baja, Puerto Rico. Recalled by: Parke Davis, Division of Warner- Lambert Company, Morris Plains, New Jersey, by letter April 12, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; Approximately 38,968 units were distributed. Reason: Lot 16101VA does not meet disintegration specifications. Lots 07751VA and 07751VB do not meet dissolution specifications.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth